BOQI International Medical Enters into MOU to acquire Chongqing Shanfeng Zhiyuan Biotechnology
Rhea-AI Summary
BOQI International Medical Inc. (NASDAQ: BIMI) announced its plan to acquire Chongqing Shanfeng Zhiyuan Biotechnology Co., Ltd. via a Memorandum of Understanding (MOU). Chongqing Shanfeng Zhiyuan specializes in medical devices, disinfection supplies, and cosmetics, operating from a facility of 18,298 sq. ft. with 51 employees. The acquisition aims to enhance BIMI's market presence in Southwest China and is expected to be finalized within 1-2 months, pending regulatory approvals. The purchase price will be determined based on a third-party appraisal of Chongqing Shanfeng Zhiyuan's fair market value.
Positive
- Acquisition enhances BIMI's market penetration in Southwest China.
- Chongqing Shanfeng Zhiyuan's innovative products complement BIMI's portfolio.
- Potential for increased revenue through expanded customer solutions.
Negative
- Integration challenges may arise post-acquisition.
- Regulatory approvals could delay the acquisition process.
News Market Reaction – BIMI
In the trading session that priced this news, BIMI gained 9.92%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
New York, May 18, 2020 (GLOBE NEWSWIRE) -- BOQI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”) today announced that it has entered into a Memorandum of Understanding (“MOU”) to acquire Chongqing Shanfeng Zhiyuan Biotechnology Co., Ltd. (“Chongqing Shanfeng Zhiyuan”) through its wholly-owned subsidiary Beijing Xin Rong Xin Industrial Development Co., Ltd.
Chongqing Shanfeng Zhiyuan is an innovator, manufacturer and supplier of medical devices, disinfection supplies and cosmetics in Southwest China. It has a manufacturing plant covering about 18,298 square feet and has 51 employees including a 6-person R&D team. Chongqing Shanfeng Zhiyuan's products include hand sanitizers, skin care products, antipruritic ointments, hemostatic toothpaste, antimicrobial agents, washing machine cleaners, etc. Its independently-developed drug “Jifukang” is used to prevent and treat diabetic peripheral neuropathy.
Pursuant to the MOU, Beijing Xin Rong Xin Industrial Development plans to purchase
"The acquisition is in line with our expansion strategy, which focuses on deeper penetration of the healthcare market in Southwest China and achieving a wider footprint nationwide," said Mr. Tiewei Song, Chief Executive Officer and President of BOQI International Medical Inc. "We are impressed by the management team and Chongqing Shanfeng Zhiyuan's ability to innovate to serve the evolving needs of its customers. Furthermore, their operating resources and customer network can enhance our market position and accelerate the development of new customer solutions. We look forward to working alongside the team at Chongqing Shanfeng Zhiyuan to drive the continued growth of the company."
About BOQI International Medical Inc.
BOQI International Medical Inc. (formerly known as NF Energy Saving Corporation) (NASDAQ: BIMI) was founded in 2006. In February 2019, the Board of Directors of the company was reorganized following efforts led by Mr. Yongquan Bi, the company’s new Chairman, with a renewed focus on the health industry. The company is now transforming from a provider of integrated energy conservation solutions utilizing energy-saving equipment, technical services and energy management re-engineering project operations to a health service provider. BOQI International Medical Inc. offers a broad range of consumer-directed health products and related services, including medical, pharmacy and behavioral health plans.
Safe Harbor Statement
The statements contained herein that are not historical facts are considered “forward-looking statements.” Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” or “anticipates” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, statements regarding the efficacy of investment in research and development are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the effect of political, economic, and market conditions and geopolitical events; legislative and regulatory changes that affect our business; the availability of funds and working capital; the actions and initiatives of current and potential competitors; investor sentiment; and our reputation. We do not undertake any responsibility to publicly release any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this report. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events, which may cause actual results to differ from those expressed or implied by any forward-looking statements. The factors discussed herein are expressed from time to time in our filings with the Securities and Exchange Commission available at http://www.sec.gov.
IR Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BIMI@dgipl.com